We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Daratumumab rapidly reduces high‐titre factor VIII inhibitors in haemophilia A patients during life‐threatening haemorrhages.
- Authors
Moonla, Chatphatai; Uaprasert, Noppacharn; Watanaboonyongcharoen, Phandee; Meesanun, Mukmanee; Sukperm, Autcharaporn; Jantasing, Ratchaneekorn; Faknuam, Saruta; Chanswangphuwana, Chantiya; Polprasert, Chantana; Sodsai, Pimpayao; Akkawat, Benjaporn; Hirankarn, Nattiya; Bunworasate, Udomsak; Rojnuckarin, Ponlapat
- Abstract
Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages Alloantibodies against factor VIII (FVIII), arising in 20%-35% of severe haemophilia A patients, significantly increase both haemophilia-related mortality and the financial burden due to the high cost of bypassing agents (BAs) and immune tolerance induction (ITI). Despite detectable low-level inhibitors, the patient achieved a partial response with 75.3% recovery of FVIII activity (FVIII:C) and an infused FVIII half-life (T/2) of 9.4 hours. Although we could not evaluate plasma cells in the bone marrow and FVIII-specific IgG in the plasma, peripheral CD19 SP + sp B cells were depleted in all patients (Figure S1), and class-switched memory B-cell counts were persistently low despite B-cell reconstitution14 postdaratumumab (Figure S2).
- Subjects
BLOOD coagulation factor VIII antibodies; BORTEZOMIB; HEMOPHILIA
- Publication
Haemophilia, 2021, Vol 27, Issue 1, pe155
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.14118